PLX vs SGEN
Protalix Biotherapeutics Inc (PLX) versus SGEN (SGEN) — a side-by-side from cached financials, not a winner call.
Protalix Biotherapeutics Inc (PLX) is a biotechnology company listed on US.
SGEN (SGEN) common stock.
Latest reported PLX revenue for 2026-06-30 was $53.6M. Net income was $22.1M. Revenue was up 59.0% from 2026-03-31 to 2026-06-30. PLX currently screens at market cap $122.6M and trailing P/E 30.8.
SGEN does not have a complete income-statement cache yet.
PLX currently screens at market cap $122.6M and trailing P/E 30.8.
Not investment advice. Open the PLX and SGEN stock pages for the full models.
Not investment advice.